Shares of Blueprint Medicines Corp (NASDAQ:BPMC) fell 6.7% during mid-day trading on Monday . The stock traded as low as $75.76 and last traded at $75.88. 562,403 shares traded hands during trading, an increase of 28% from the average session volume of 440,141 shares. The stock had previously closed at $81.30.
Several brokerages have issued reports on BPMC. Zacks Investment Research raised shares of Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 target price on the stock in a research note on Tuesday, April 30th. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Thursday, March 28th. BidaskClub downgraded shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 16th. Wedbush reaffirmed an “outperform” rating on shares of Blueprint Medicines in a research note on Tuesday, February 26th. Finally, ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 10th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $102.17.
The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.59 and a current ratio of 6.59. The company has a market capitalization of $3.97 billion, a price-to-earnings ratio of -15.06 and a beta of 1.53.
Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.83) by ($0.15). Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. The company had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.38 million. During the same period last year, the company posted ($1.29) earnings per share. The company’s revenue was down 23.2% compared to the same quarter last year. Equities research analysts predict that Blueprint Medicines Corp will post -7.76 EPS for the current fiscal year.
In related news, COO Kate Haviland sold 21,644 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $85.05, for a total value of $1,840,822.20. Following the completion of the sale, the chief operating officer now directly owns 20,018 shares in the company, valued at $1,702,530.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ariel Hurley sold 415 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $85.55, for a total transaction of $35,503.25. Following the completion of the sale, the insider now owns 415 shares of the company’s stock, valued at $35,503.25. The disclosure for this sale can be found here. Insiders sold 44,359 shares of company stock worth $3,798,843 over the last ninety days. 3.15% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of BPMC. Hillhouse Capital Advisors Ltd. bought a new stake in Blueprint Medicines in the fourth quarter worth $77,142,000. Norges Bank bought a new stake in Blueprint Medicines in the fourth quarter worth $42,705,000. Perceptive Advisors LLC boosted its holdings in Blueprint Medicines by 48.3% in the first quarter. Perceptive Advisors LLC now owns 1,271,054 shares of the biotechnology company’s stock worth $101,748,000 after purchasing an additional 413,728 shares in the last quarter. FMR LLC boosted its holdings in Blueprint Medicines by 5.3% in the first quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock worth $555,491,000 after purchasing an additional 346,738 shares in the last quarter. Finally, Foresite Capital Management III LLC boosted its holdings in Blueprint Medicines by 133.8% in the fourth quarter. Foresite Capital Management III LLC now owns 467,682 shares of the biotechnology company’s stock worth $25,213,000 after purchasing an additional 267,682 shares in the last quarter. Hedge funds and other institutional investors own 93.93% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Blueprint Medicines (BPMC) Shares Down 6.7%” was posted by Highlight Press and is the sole property of of Highlight Press. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://highlightpress.com/2019/05/22/blueprint-medicines-bpmc-shares-down-6-7.html.
About Blueprint Medicines (NASDAQ:BPMC)
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Read More: Limitations of the P/E Growth ratio
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.